scholarly journals Seasonal influenza vaccination and the risk of infection with pandemic influenza: a possible illustration of non-specific temporary immunity following infection

2010 ◽  
Vol 15 (47) ◽  
Author(s):  
H Kelly ◽  
S Barry ◽  
K Laurie ◽  
G Mercer
Keyword(s):  
Influenza Vaccine ◽  
Pandemic Influenza ◽  
Influenza A ◽  
Seasonal Influenza ◽  
Influenza Infection ◽  
Risk Of Infection ◽  
Seasonal Influenza Vaccine ◽  
Influenza A H1n1 ◽  
Seasonal Infection ◽  
Temporary Immunity

Four Canadian studies have suggested that receipt of seasonal influenza vaccine increased the risk of laboratory-confirmed infection with 2009 pandemic influenza A(H1N1). During the influenza season of 2009 in Victoria, Australia, this virus comprised 97% of all circulating influenza viruses for which sub-typing was available. We found no evidence that seasonal influenza vaccine increased the risk of, or provided protection against, infection with the pandemic virus. Ferret experiments have suggested protection against pandemic influenza A(H1N1) 2009 from multiple prior seasonal influenza infections but not from prior seasonal vaccination. Modelling studies suggest that influenza infection leads to heterosubtypic temporary immunity which is initially almost complete. We suggest these observations together can explain the apparent discrepant findings in Canada and Victoria. In Victoria there was no recent prior circulation of seasonal influenza and thus no temporary immunity to pandemic influenza. There was no association of seasonal influenza vaccine with pandemic influenza infection. In Canada seasonal influenza preceded circulation of the pandemic virus. An unvaccinated proportion of the population developed temporary immunity to pandemic influenza from seasonal infection but a proportion of vaccinated members of the population did not get seasonal infection and hence did not develop temporary immunity to pandemic influenza. It may therefore have appeared as if seasonal vaccination increased the risk of infection with pandemic influenza A(H1N1) virus.

scholarly journals Effectiveness of pandemic and seasonal influenza vaccine in preventing pandemic influenza A(H1N1)2009 infection in England and Scotland 2009-2010

2011 ◽  
Vol 16 (2) ◽  
Author(s):  
P Hardelid ◽  
D M Fleming ◽  
J McMenamin ◽  
N Andrews ◽  
C Robertson ◽  
...  
Keyword(s):  
Influenza Vaccine ◽  
Pandemic Influenza ◽  
Influenza A ◽  
Seasonal Influenza ◽  
Seasonal Influenza Vaccine ◽  
Binary File ◽  
Influenza A H1n1

Binary file ES_Abstracts_Final_ECDC.txt matches

AF03-adjuvanted and non-adjuvanted pandemic influenza A (H1N1) 2009 vaccines induce strong antibody responses in seasonal influenza vaccine-primed and unprimed mice

Vaccine ◽  
2010 ◽  
Vol 28 (18) ◽  
pp. 3076-3079 ◽  
Author(s):  
Catherine Caillet ◽  
Fabienne Piras ◽  
Marie-Clotilde Bernard ◽  
Aymeric de Montfort ◽  
Florence Boudet ◽  
...  
Keyword(s):  
Influenza Vaccine ◽  
Pandemic Influenza ◽  
Influenza A ◽  
Seasonal Influenza ◽  
Antibody Responses ◽  
Seasonal Influenza Vaccine ◽  
Influenza A H1n1

Pandemic influenza A/H1N1 vaccine administered sequentially or simultaneously with seasonal influenza vaccine to HIV-infected children and adolescents

Vaccine ◽  
2011 ◽  
Vol 29 (8) ◽  
pp. 1677-1682 ◽  
Author(s):  
Susanna Esposito ◽  
Laura Tagliaferri ◽  
Cristina Daleno ◽  
Antonia Valzano ◽  
Irene Picciolli ◽  
...  
Keyword(s):  
Influenza Vaccine ◽  
Children And Adolescents ◽  
Pandemic Influenza ◽  
Influenza A ◽  
Seasonal Influenza ◽  
H1n1 Vaccine ◽  
Seasonal Influenza Vaccine ◽  
Influenza A H1n1

scholarly journals Effectiveness of the 2009 seasonal influenza vaccine against pandemic influenza A(H1N1)2009 in healthcare workers in New Zealand, June-August 2009

2011 ◽  
Vol 16 (2) ◽  
Author(s):  
S Jefferies ◽  
D Earl ◽  
N Berry ◽  
T Blackmore ◽  
S Rooker ◽  
...  
Keyword(s):  
New Zealand ◽  
Influenza Vaccine ◽  
Pandemic Influenza ◽  
Healthcare Workers ◽  
Influenza A ◽  
Seasonal Influenza ◽  
Seasonal Influenza Vaccine ◽  
Binary File ◽  
Influenza A H1n1

Binary file ES_Abstracts_Final_ECDC.txt matches

Influenza A H1N1 2009 Vaccine in Patients with Hematological Diseases: Good Safety and Immunogenicity Even in Heavily Chemotherapy-Treated Patients

Blood ◽  
2012 ◽  
Vol 120 (21) ◽  
pp. 1054-1054
Author(s):  
Honar Cherif ◽  
Martin Hoglund ◽  
Karlis Pauksens
Keyword(s):  
Influenza Vaccine ◽  
Research Funding ◽  
Influenza A ◽  
Seasonal Influenza ◽  
Hematological Malignancies ◽  
World Health ◽  
Influenza B ◽  
Seasonal Influenza Vaccine ◽  
Hematological Diseases ◽  
Influenza A H1n1

Abstract Abstract 1054 Background: Patients with hematological malignancies are more susceptible for viral infections including influenza, which may be associated with prolonged illness, increased morbidity and mortality. In 2009, the World Health Organization classified the novel influenza A(H1N1) virus as pandemic. The impact of this viral infection in patients (pts) with hematological disorders was unknown, and there were concerns about the risk of serious complications. In Sweden, institutional guidelines recommended two doses of the AS03-adjuvanted inactivated H1N1 split vaccine Pandemrix™ from GlaxoSmithKline in these pts. Aims: Prospectively determine the safety, immunogenicity, and clinical efficacy of influenza A (H1N1) 2009 vaccination in patients with hematological diseases. Compare the immunological response to that obtained by the trivalent seasonal influenza vaccine (TIV). Patients and methods: 31 pts were included (myeloma 9, CLL 5, AML 6, ALL 2, CML 2, others 5), out of which 13 had undergone hematopoietic stem cell transplantation (HSCT). All received influenza A(H1N1) 2009 vaccine at day 0, and 28, and the majority (n=25) seasonal influenza vaccine at day 56. Serum for antibody analyses by validated HI-assays was taken at day 0, 28, 56 and 86 and at 1 year. The response to vaccination (seroconversion) was defined as at least a four-fold increase in antibody titer after vaccination or, in case prevaccination HI-titer was < 10, a post-vaccination titer of HI > 40 or greater. Considering that the HI-assay for influenza B differed from the A strains only the seroconversion rate was considered for the influenza B. Results: The A (H1N1) vaccine was well tolerated and no severe adverse events were reported. At day 28, a total of 16(52%) patients had protective levels of antibodies to A (H1N1) 2009 and 15(48%) had a seroconversion response. After the second dose of the vaccine, 25(81%) reached both protective levels of antibodies and seroconversion. At 1 year, protective levels of antibodies against A (H1N1) 2009 remained in 56% of responding patients. Seroconversion response was observed in 9/13 patients who had undergone HSCT, including 5/9 pts who had been transplanted within1–5 months, as well as in all (n=9) pts with myeloma having advanced disease and/or ongoing intense treatment. Following vaccination with TIV and evaluated at day 86, protective antibody levels and seroconversion response against A/Brisbane/59/2007 H1N1-like virus were detected in 10(40%) respective 7(28%), and against A/Uruguay/10/2007/H3N2-like virus in 14(56%) respective 10(40%). As for B/Brisbane/60/2008-like virus, seroconversion response was found in 5(20%) of all pts. Response to the pandemic influenza A (H1N1) 2009 vaccine was better than that to the three TIV strains (p<0.001, p<0.009 and p<0.001 respectively). Conclusion: A substantial proportion of patients with hematological malignancies including even heavily treated Myeloma and HSCT patients mounted a good response to the adjuvanted influenza A (H1N1) 2009 vaccine. This vaccine was well tolerated and had a significantly better immunogenicity than that of the non-adjuvanted seasonal influenza vaccine. Disclosures: Cherif: GSK: Research Funding. Pauksens:GSK: Research Funding.

scholarly journals Circulating influenza viruses and the effectiveness of seasonal influenza vaccine in Romania, season 2012-2013 / Virusurile gripale circulante și eficacitatea vaccinului gripal sezonier în România, în sezonul 2012-2013

2015 ◽  
Vol 23 (1) ◽  
Author(s):  
Daniela Pitigoi ◽  
George Necula ◽  
Viorel Alexandrescu ◽  
Maria Elena Mihai ◽  
Carmen Maria Cherciu ◽  
...  
Keyword(s):  
Influenza Vaccine ◽  
Vaccine Strain ◽  
Influenza A ◽  
Seasonal Influenza ◽  
Influenza Viruses ◽  
Nucleotide Sequencing ◽  
Influenza B ◽  
Seasonal Influenza Vaccine ◽  
Negative Case ◽  
Influenza A H1n1

AbstractBackgound. Using influenza epidemiological and virological surveillance data, we aimed at investigating the profile of influenza viruses circulating in Romania during the season 2012-2013 and estimating the effectiveness (VE) of the seasonal vaccine. Methods. We tested all specimens collected from patients with influenza like illness (ILI) in the national surveillance system between week 40/2012 to week 20/2013. Influenza A/B positive specimens identified by molecular detection (RT-PCR) were further characterized. We used hemagglutination inhibition assay for antigenic characterization and chemiluminiscence assay for the antiviral susceptibility testing. Subsequently we conducted nucleotide sequencing of hemagglutinin and neuraminidase genes and phylogenetic tree analyses. We estimated influenza VE using the test negative case-control study design, as 1-odds ratio of vaccination among ILI cases positive for influenza and ILI negative controls. Results and Discussions. We tested 1087 specimens, and 537 cases were positive (56.2% influenza B, 40.6% A(H1N1)pdm09, 3.2% A(H3N2). Sixty-four influenza viruses were antigenically and/or genetically characterized. A(H1N1)pdm09 viruses were related to the vaccine strain A/ California/07/2009 and clustered with genetic group 6 similar to A/St. Petersburg/27/2011. Influenza B viruses belonged to clade 2 of type B/Yamagata lineage, related to B/Estonia/55669/2011 except one, B/Victoria lineage, representative strain B/Brisbane/60/2008. A(H3) viruses clustered with group 3C of the A/Victoria/208/2009 clade, similar to the vaccine strain A/Victoria/361/2011. All tested strains (57) demonstrated susceptibility to oseltamivir and zanamivir. The adjusted seasonal influenza vaccine effectiveness against influenza A(H1N1)pdm09 (N=119) was 76.9% (95% CI: -113.4, 98.5), suggesting a good protection, consistent with the good match between the vaccine and circulating strains.

Sign in / Sign up

Export Citation Format

Share Document